| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 2/6 |
| Past Performance | 6/6 |
| Financial Health | 6/6 |
| Dividends | 3/6 |
1093 Overview
CSPC Pharmaceutical Group Limited, an investment holding company, engages in the research and development, manufacture, and sale of pharmaceutical products in the People’s Republic of China, other Asian regions, the Americas, Europe, and internationally.
Rewards
Risk Analysis
No risks detected for 1093 from our risk checks.
CSPC Pharmaceutical Group Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | HK$9.49 |
| 52 Week High | HK$7.08 |
| 52 Week Low | HK$12.68 |
| Beta | 0.69 |
| 1 Month Change | -9.96% |
| 3 Month Change | -17.76% |
| 1 Year Change | -1.91% |
| 3 Year Change | 6.43% |
| 5 Year Change | 132.71% |
| Change since IPO | 2,149.48% |
Recent News & Updates
CSPC Pharmaceutical Group (HKG:1093) Is Increasing Its Dividend To HK$0.08
CSPC Pharmaceutical Group Limited ( HKG:1093 ) has announced that it will be increasing its dividend on the 8th of...
CSPC Pharmaceutical Group Limited (HKG:1093) Shares Could Be 40% Below Their Intrinsic Value Estimate
Does the August share price for CSPC Pharmaceutical Group Limited ( HKG:1093 ) reflect what it's really worth? Today...
Do CSPC Pharmaceutical Group's (HKG:1093) Earnings Warrant Your Attention?
Some have more dollars than sense, they say, so even companies that have no revenue, no profit, and a record of falling...
Shareholder Returns
| 1093 | HK Pharmaceuticals | HK Market | |
|---|---|---|---|
| 7D | -0.3% | -4.4% | -4.9% |
| 1Y | -1.9% | -13.7% | 5.6% |
Return vs Industry: 1093 exceeded the Hong Kong Pharmaceuticals industry which returned -13.7% over the past year.
Return vs Market: 1093 underperformed the Hong Kong Market which returned 5.6% over the past year.
Price Volatility
| 1093 volatility | |
|---|---|
| 1093 Beta | 0.69 |
| Industry Beta | 0.59 |
| Market Beta | 1 |
Stable Share Price: 1093 is not significantly more volatile than the rest of Hong Kong stocks over the past 3 months, typically moving +/- 6% a week.
Volatility Over Time: 1093's weekly volatility (6%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1992 | 23,300 | Dongchen Cai | https://www.cspc.com.hk |
CSPC Pharmaceutical Group Limited, an investment holding company, engages in the research and development, manufacture, and sale of pharmaceutical products in the People’s Republic of China, other Asian regions, the Americas, Europe, and internationally. It operates through Finished Drugs, Bulk Products, and Functional Food and Others segments. The company provides NBP soft capsules and injections for acute ischemic stroke and memory and mental impairment; Oulaining capsules and injections to treat mild to moderate memory and mental impairment; Xuanning for hypertension; Duomeisu for lymphoma, multiple myeloma, ovarian and breast cancers, and other malignant tumors; Jinyouli to prevent leucopenia and infection induced by chemotherapy; Enxi to treat adult idiopathic Parkinson’s disease; Keaili for breast cancer; Shuluoke, Nuomoling, Weihong, and Xinweihong for various infections; and Encun to prevent atherosclerotic thrombosis events.
Valuation
Is CSPC Pharmaceutical Group undervalued compared to its fair value and its price relative to the market?
45.8%
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: 1093 (HK$9.49) is trading below our estimate of fair value (HK$17.52)
Significantly Below Fair Value: 1093 is trading below fair value by more than 20%.
Price To Earnings Ratio
PE vs Industry: 1093 is poor value based on its PE Ratio (15.9x) compared to the Hong Kong Pharmaceuticals industry average (9.7x).
PE vs Market: 1093 is poor value based on its PE Ratio (15.9x) compared to the Hong Kong market (9.8x).
Price to Earnings Growth Ratio
PEG Ratio: 1093 is poor value based on its PEG Ratio (1.4x)
Price to Book Ratio
PB vs Industry: 1093 is overvalued based on its PB Ratio (3.8x) compared to the HK Pharmaceuticals industry average (1.1x).
Future Growth
How is CSPC Pharmaceutical Group forecast to perform in the next 1 to 3 years based on estimates from 25 analysts?
11.8%
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: 1093's forecast earnings growth (11.8% per year) is above the savings rate (1.5%).
Earnings vs Market: 1093's earnings (11.8% per year) are forecast to grow slower than the Hong Kong market (17.1% per year).
High Growth Earnings: 1093's earnings are forecast to grow, but not significantly.
Revenue vs Market: 1093's revenue (11.5% per year) is forecast to grow slower than the Hong Kong market (12.3% per year).
High Growth Revenue: 1093's revenue (11.5% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: 1093's Return on Equity is forecast to be high in 3 years time (20.8%)
Past Performance
How has CSPC Pharmaceutical Group performed over the past 5 years?
24.4%
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: 1093 has high quality earnings.
Growing Profit Margin: 1093's current net profit margins (22.6%) are higher than last year (17.6%).
Past Earnings Growth Analysis
Earnings Trend: 1093's earnings have grown significantly by 24.4% per year over the past 5 years.
Accelerating Growth: 1093's earnings growth over the past year (42.4%) exceeds its 5-year average (24.4% per year).
Earnings vs Industry: 1093 earnings growth over the past year (42.4%) exceeded the Pharmaceuticals industry 23.8%.
Return on Equity
High ROE: 1093's Return on Equity (23.7%) is considered high.
Financial Health
How is CSPC Pharmaceutical Group's financial position?
Financial Position Analysis
Short Term Liabilities: 1093's short term assets (CN¥19.1B) exceed its short term liabilities (CN¥6.9B).
Long Term Liabilities: 1093's short term assets (CN¥19.1B) exceed its long term liabilities (CN¥624.4M).
Debt to Equity History and Analysis
Debt Level: 1093 is debt free.
Reducing Debt: 1093 has no debt compared to 5 years ago when its debt to equity ratio was 17.4%.
Debt Coverage: 1093 has no debt, therefore it does not need to be covered by operating cash flow.
Interest Coverage: 1093 has no debt, therefore coverage of interest payments is not a concern.
Balance Sheet
Dividend
What is CSPC Pharmaceutical Group current dividend yield, its reliability and sustainability?
1.78%
Current Dividend Yield
Dividend Yield vs Market
Notable Dividend: 1093's dividend (1.78%) isn’t notable compared to the bottom 25% of dividend payers in the Hong Kong market (2.29%).
High Dividend: 1093's dividend (1.78%) is low compared to the top 25% of dividend payers in the Hong Kong market (6.87%).
Stability and Growth of Payments
Stable Dividend: 1093's dividend payments have been volatile in the past 10 years.
Growing Dividend: 1093's dividend payments have increased over the past 10 years.
Current Payout to Shareholders
Dividend Coverage: With its reasonably low payout ratio (28.3%), 1093's dividend payments are well covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: 1093's dividends in 3 years are forecast to be well covered by earnings (28.3% payout ratio).
Next Steps
Management
How experienced are the management team and are they aligned to shareholders interests?
3.1yrs
Average management tenure
CEO
Dongchen Cai (67 yo)
no data
Tenure
CN¥11,841,000
Compensation
Mr. Dongchen Cai serves as an Executive Chairman and Chief Executive Officer of CSPC Pharmaceutical Group Limited (formerly, China Pharmaceutical Group Limited) and has been its Executive Director since Ap...
CEO Compensation Analysis
Compensation vs Market: Dongchen's total compensation ($USD1.83M) is above average for companies of similar size in the Hong Kong market ($USD1.02M).
Compensation vs Earnings: Dongchen's compensation has been consistent with company performance over the past year.
Leadership Team
Experienced Management: 1093's management team is considered experienced (3.1 years average tenure).
Board Members
Experienced Board: 1093's board of directors are considered experienced (5.3 years average tenure).
Ownership
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Ownership Breakdown
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Top Shareholders
Company Information
CSPC Pharmaceutical Group Limited's employee growth, exchange listings and data sources
Key Information
- Name: CSPC Pharmaceutical Group Limited
- Ticker: 1093
- Exchange: SEHK
- Founded: 1992
- Industry: Pharmaceuticals
- Sector: Pharmaceuticals & Biotech
- Market Cap: HK$113.449b
- Shares outstanding: 11.95b
- Website: https://www.cspc.com.hk
Number of Employees
Location
- CSPC Pharmaceutical Group Limited
- No. 226 Huanghe Street
- Shijiazhuang
- Hebei Province
- 50035
- China
Listings
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2021/09/22 10:02 |
| End of Day Share Price | 2021/09/21 00:00 |
| Earnings | 2021/06/30 |
| Annual Earnings | 2020/12/31 |
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.